Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.05 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.68M
Market Cap
$1.28B
Enterprise Value$2.31B
Total Cash (Recent Filing)$1.66M
Total Debt (Recent Filing)$5.91M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Apr 29, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding128,656,900
10 Day Avg. Volume1,583,353
30 Day Avg. Volume1,678,308
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-1.53K
Forecast
1Y Price Target
$16.78Price Target Upside68.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Pathline LLC provides NeoGenomics with a strengthened commercial presence in the Northeast, faster turnaround times, and incremental volume for its higher-margin molecular testing.
Product DevelopmentNeoGenomics is pursuing a strategy of launching several smaller, line extension products each year, expected to contribute to long-term sales growth.
ValuationShares offer compelling long-term upside with current valuation underappreciating growth and profitability potential.
Bears Say
CEO ChangeShares are off 46% following a surprise CEO change and a slight miss to first-quarter revenue consensus.
Financial PerformanceThe company expects a net loss of ($85)-($76) million for the full year 2025, partly due to increased stock compensation and other expenses.
Revenue ImpactGross margins for the Pathline acquisition are below NeoGenomics Inc.'s average, and revenues per test are expected to temporarily decrease.
---
Ownership Overview
1.04% Insiders
35.30% Mutual Funds
0.13% Other Institutional Investors
38.14% Public Companies and
Individual Investors
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $8.05 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.28B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Apr 29, 2025 which is today.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Feb 18, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.029 by $0.011.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is -0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,656,900 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.04 in its last earnings report, beating expectations of $0.029. Following the earnings report the stock price went down -14.008%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.78 (68.30% Upside)
$16.78 (68.30% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 345.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.49%
12-Months-Change
Fundamentals
Return on Equity
-8.54%
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading cancer diagnostics and pharmaceutical services company providing comprehensive testing services to hospitals, pathologists, oncologists, and other healthcare providers across the United States. The company specializes in cancer genetics testing and information services, offering a broad menu of diagnostic tests that include cytogenetics, flow cytometry, FISH, IHC, and molecular testing. It aims to improve patient care through high-quality genetic and molecular testing services, enabling a better understanding of cancer and patient outcomes.
---
NEO Company Deck
---
NEO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
NeoGenomics demonstrated strong revenue growth and financial improvement, particularly in its NGS segment and adjusted EBITDA. However, challenges in the pharma segment and ongoing legal issues with RaDaR tempered the overall positive performance.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$16.78
▲(68.30% Upside)
Technical Analysis
---